Condition
Steatotic Liver Disease
Total Trials
6
Recruiting
2
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 1 (1)
Trial Status
Not Yet Recruiting2
Completed2
Recruiting2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT07537829CompletedPrimary
Risk Factors and Prediction Model for Liver-Related Outcomes in Elderly Patients With Steatotic Liver Disease
NCT06823713Phase 1Recruiting
RTX001 Autologous Engineered Macrophages for Liver Cirrhosis
NCT07270822Not ApplicableNot Yet RecruitingPrimary
Screening for MASLD-related Advanced Fibrosis in Type 2 Diabetes
NCT06907563Not Yet RecruitingPrimary
Long-term Follow-up to Determine Outcome in Liver Disease (LOVE Study)
NCT04721665RecruitingPrimary
German SLD-Registry (Deutsches SLD-Register)
NCT06352697Not ApplicableCompleted
Probiotic Lysate (Postbiotic and Metabiotic) Supplementation for Adults MASLD Patients (DELI_MASLD Study)
Showing all 6 trials